1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy

 
• By Derrick Gingery

US FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee votes in favor of efficacy of proposed glaucoma treatment, but several say only in patients with baseline intraocular pressure less than 25 mmHg.

Eye
The advisory committee voted that efficacy outweighed netarsudil's safety issues.

The efficacy of Aerie Pharmaceuticals Inc.'s glaucoma treatment netarsudil may be limited to patients with low intraocular pressure, but the company does not expect that to be reflected in the indication.

Aerie is seeking US approval for once-daily netarsudil, proposed trade name Rhopressa, approved for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers